Caladrius Biosciences is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease.[2]
 | |
| Company type | Public |
|---|---|
| Nasdaq: CLBS Russell Microcap Index component | |
| Industry | Biopharmaceuticals |
| Headquarters | Basking Ridge, New Jersey[1], United States |
Key people | David J. Mazzo (CEO) |
| Website | caladrius |
Founded in 1980,[3] the company was formerly known as Corniche Group Inc, Phase III Medical Inc,[4] and NeoStem, Inc., it adopted its current name in 2015.[3]
In 2022, Caladrius and Cend Therapeutics merged to form Lisata Therapeutics.[5]
Cardiovascular disease edit
In 2012 it started a randomized, controlled, double-blind phase 2 clinical trial of AMR-001 (NBS10), an autologous bone marrow-derived cell therapy enriched for CD34+ cells, for marked reduction in left ventricular function following acute myocardial infarction.[6]
The published study results showed no evidence of benefit from pre-specified endpoints, though there appeared to be evidence suggesting possible dose-related benefit in post-hoc analysis from a subset of patients. [7]
References edit
- ^ Editorial, Reuters. "CLBS.PH - Caladrius Biosciences Inc Profile | Reuters". www.reuters.comundefined.
{{cite web}}:|first1=has generic name (help) - ^ NeoStem CEO Discusses Adult Stem Cell Therapies, May 14, 2012. Bloomberg Television. 3m35s video. Accessed September 2015.
- ^ a b "Caladrius Biosciences - Consensus Indicates Potential 316.7% Upside - DirectorsTalk Interviews". Retrieved 2021-05-03.
- ^ EDGAR Search Results – Neostem, EDGAR
- ^ Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics, September 15, 2022
- ^ NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction (PreSERVE-AMI)
- ^ Arshad A. Quyyumi (2017). "PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI". Circulation Research. 120 (2): 324–331. doi:10.1161/CIRCRESAHA.115.308165. PMC 5903285. PMID 27821724.